

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034932 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) A61K 39/09 (2006.01)
A61K 47/02 (2006.01) A61K 39/385 (2006.01)
A61P 31/04 (2006.01) A61K 47/64 (2017.01)

(21) International Application Number:

PCT/US2022/075859

(22) International Filing Date:

01 September 2022 (01.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/240,244 02 September 2021 (02.09.2021) US

(71) Applicant: **VAXCYTE, INC.** [US/US]; 825 Industrial Road, Suite 300, San Carlos, California 94070 (US).

(72) Inventors: **GRAINGER, Christopher Iain**; c/o Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California 94070 (US). **BARBANEL, Sandrine**; c/o Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California

94070 (US). **ATWE, Shashwati Ujwalkumar**; c/o Vaxcyte, Inc., 825 Industrial Road, Suite 300, San Carlos, California 94070 (US).


(74) Agent: **MAYER, Mika R.** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE

FIG. 2



(57) Abstract: The present disclosure provides stabilized vaccine compositions that resist the formation of unsuitable adjuvant flocculant or aggregates. These compositions comprise an aluminium adjuvant, a non-aluminium phosphate salt, sodium chloride and a polypeptide-polysaccharide conjugate comprising at least two non-natural amino acids. The present disclosure further provides methods of using such compositions to induce immune responses against infections in subjects.

[Continued on next page]

WO 2023/034932 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*